Apoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Park, Sumi ^a   Han, Ji Man ^a   Cheon, Jun ^a   Hwang, Jong Ik ^a   Seong, Jae Young ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYTOCHROME C; GONADORELIN ANTAGONIST; LACTATE DEHYDROGENASE; LIPOCORTIN 5; REACTIVE OXYGEN METABOLITE; SN09 2; TRP 1; UNCLASSIFIED DRUG; ACETYL-(2-NAPHTHYLALANYL)(2)-4-CHLOROPHENYLALANYL-(3-PYRIDYL)ALANYL(3)-SERYL-TYROSYL-N5-AMINOCARBONYLORNITHYL-TRYPTOPHYL-TYROSYL-PROLYL-ALANINAMINE; ANTINEMATODAL AGENT; GONADORELIN; LHRH, HIS(5)-TRP(7)-TYR(8)-; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG ACCUMULATION; ENZYME ACTIVATION; ENZYME RELEASE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; METABOLISM; NUDE MOUSE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEMATODAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYTOCHROMES C; GONADOTROPIN-RELEASING HORMONE; HUMANS; LACTATE DEHYDROGENASES; MALE; MICE; MICE, NUDE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84903119934     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099723     Document Type: Article

References (47)

1. Abou-Kheir W, Hynes PG, Martin P, Yin JJ, Liu YN, et al. (2011) Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity. PLoS One 6: e26112.
2. Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53: 171-184.
3. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
4. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300. (Pubitemid 27318990)
5. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN (2002) Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81: 191-201. (Pubitemid 34879930)
6. Cook T, Sheridan WP (2000) Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 5: 162-168. (Pubitemid 30238236)
7. Eisenberger MA, O'Dwyer PJ, Friedman MA (1986) Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 4: 414-424. (Pubitemid 16133096)
8. Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M (1998) Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 83: 3826-3831. (Pubitemid 28513557)
9. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, et al. (1996) Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81: 3930-3937. (Pubitemid 26380398)
10. Marelli MM, Moretti RM, Dondi D, Motta M, Limonta P (1999) Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140: 329-334. (Pubitemid 29011176)
11. Kraus S, Levy G, Hanoch T, Naor Z, Seger R (2004) Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 64: 5736-5744. (Pubitemid 39095572)
12. Tiwary BK (2013) Correlated evolution of gonadotropin-releasing hormone and gonadotropin-inhibitory hormone and their receptors in mammals. Neuroendocrinology 97: 242-251.
13. Sherwood NM, Lovejoy DA, Coe IR (1993) Origin of mammalian gonadotropin-releasing hormones. Endocr Rev 14: 241-254. (Pubitemid 23118420)
14. Sealfon SC, Weinstein H, Millar RP (1997) Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 18: 180-205. (Pubitemid 27171519)
15. White RB, Eisen JA, Kasten TL, Fernald RD (1998) Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci U S A 95: 305-309. (Pubitemid 28103949)
16. Okada Y, Murota-Kawano A, Kakar SS, Winters SJ (2003) Evidence that gonadotropin-releasing hormone (GnRH) II stimulates luteinizing hormone and follicle-stimulating hormone secretion from monkey pituitary cultures by activating the GnRH I receptor. Biol Reprod 69: 1356-1361. (Pubitemid 37173872)
17. Densmore VS, Urbanski HF (2003) Relative effect of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on gonadotropin release. J Clin Endocrinol Metab 88: 2126-2134. (Pubitemid 36549888)
18. Gault PM, Maudsley S, Lincoln GA (2003) Evidence that gonadotropin-releasing hormone II is not a physiological regulator of gonadotropin secretion in mammals. J Neuroendocrinol 15: 831-839. (Pubitemid 37038608)
19. Kang SK, Tai CJ, Nathwani PS, Leung PC (2001) Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells. Endocrinology 142: 182-192. (Pubitemid 32183680)
20. Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y, et al. (2002) The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 8: 1421-1426. (Pubitemid 36019427)
21. Illing N, Troskie BE, Nahorniak CS, Hapgood JP, Peter RE, et al. (1999) Two gonadotropin-releasing hormone receptor subtypes with distinct ligand selectivity and differential distribution in brain and pituitary in the goldfish (Carassius auratus). Proc Natl Acad Sci U S A 96: 2526-2531. (Pubitemid 29117949)
22. Wang L, Bogerd J, Choi HS, Seong JY, Soh JM, et al. (2001) Three distinct types of GnRH receptor characterized in the bullfrog. Proc Natl Acad Sci U S A 98: 361-366. (Pubitemid 32095913)
23. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, et al. (2001) A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci U S A 98: 9636-9641. (Pubitemid 32769355)
24. Faurholm B, Millar RP, Katz AA (2001) The genes encoding the type II gonadotropin-releasing hormone receptor and the ribonucleoprotein RBM8A in humans overlap in two genomic loci. Genomics 78: 15-18. (Pubitemid 33043654)
25. Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR, et al. (2003) A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 144: 423-436. (Pubitemid 36205212)
26. Leung PC, Cheng CK, Zhu XM (2003) Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol 202: 145-153. (Pubitemid 36593406)
27. Maiti K, Oh DY, Moon JS, Acharjee S, Li JH, et al. (2005) Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. J Clin Endocrinol Metab 90: 4287-4298. (Pubitemid 41058211)
28. Kim DK, Yang JS, Maiti K, Hwang JI, Kim K, et al. (2009) A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells. Cancer Res 69: 923-931.
29. Davidson JS, Assefa D, Pawson A, Davies P, Hapgood J, et al. (1997) Irreversible activation of the gonadotropin-releasing hormone receptor by photoaffinity cross-linking: localization of attachment site to Cys residue in N-terminal segment. Biochemistry 36: 12881-12889. (Pubitemid 27465399)
30. Chalah A, Khosravi-Far R (2008) The mitochondrial death pathway. Adv Exp Med Biol 615: 25-45.
31. Blank M, Shiloh Y (2007) Programs for cell death: apoptosis is only one way to go. Cell Cycle 6: 686-695. (Pubitemid 46535681)
32. Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R, et al. (2004) Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 64: 7533-7544. (Pubitemid 39372098)
33. Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, et al. (2004) Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151: 141-149. (Pubitemid 39117377)
34. Grosse R, Schmid A, Schoneberg T, Herrlich A, Muhn P, et al. (2000) Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins. J Biol Chem 275: 9193-9200. (Pubitemid 30185136)
35. Sviridonov L, Dobkin-Bekman M, Shterntal B, Przedecki F, Formishell L, et al. (2013) Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines. Mol Cell Endocrinol 369: 107-118.
36. Kim KY, Choi KC, Auersperg N, Leung PC (2006) Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13: 211-220.
37. Wu HM, Wang HS, Huang HY, Lai CH, Lee CL, et al. (2013) Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2. BMC Cancer 13: 300.
38. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, et al. (2004) Gonadotropin-releasing hormone receptors. Endocr Rev 25: 235-275. (Pubitemid 38501395)
39. Szabadkai G, Bianchi K, Varnai P, De Stefani D, Wieckowski MR, et al. (2006) Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol 175: 901-911. (Pubitemid 44969196)
40. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, et al. (2007) Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131: 257-270. (Pubitemid 47576138)
41. Herman-Antosiewicz A, Johnson DE, Singh SV (2006) Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. Cancer Res 66: 5828-5835. (Pubitemid 43927137)
42. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB (2007) Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J Cell Sci 120: 4155-4166.
43. Burbulla LF, Schelling C, Kato H, Rapaport D, Woitalla D, et al. (2010) Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum Mol Genet 19: 4437-4452.
44. Deocaris CC, Kaul SC, Wadhwa R (2006) On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. Cell Stress Chaperones 11: 116-128. (Pubitemid 43948351)
45. Klionsky DJ, Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. Science 290: 1717-1721. (Pubitemid 32004796)
46. Levine B, Mizushima N, Virgin HW (2011) Autophagy in immunity and inflammation. Nature 469: 323-335.
47. Patel AS, Lin L, Geyer A, Haspel JA, An CH, et al. (2012) Autophagy in idiopathic pulmonary fibrosis. PLoS One 7: e41394.